clinical pipeline scan derived

{
  "input": {
    "type": "http",
    "method": "GET",
    "queryParams": {
      "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
      "phase": "phase2 | phase3 | both (default: both)",
      "status": "active | all (default: active — recruiting + active not recruiting)",
      "condition": "Disease or condition — e.g. \"Non-Small Cell Lung Cancer\" | \"Alzheimer Disease\" | \"Type 2 Diabetes\" | \"Crohn Disease\" | \"Multiple Myeloma\""
    }
  },
  "output": {
    "type": "json",
    "errors": {
      "400": {
        "example": {
          "error": "invalid request"
        },
        "description": "Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."
      },
      "402": {
        "description": "Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."
      },
      "500": {
        "example": {
          "error": "upstream_failed"
        },
        "description": "Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."
      }
    },
    "example": {
      "query_summary": {
        "condition": "Non-Small Cell Lung Cancer",
        "status_filter": "RECRUITING,ACTIVE_NOT_RECRUITING",
        "phases_searched": [
          "PHASE2",
          "PHASE3"
        ]
      },
      "pipeline_totals": {
        "phase2_count": 156,
        "phase3_count": 89,
        "total_active": 245
      },
      "phase3_highlights": [
        {
          "nctId": "NCT05116748",
          "title": "Pembrolizumab + Carboplatin vs SOC in NSCLC",
          "status": "RECRUITING",
          "sponsor": "Merck",
          "countries": [
            "United States",
            "Germany",
            "Japan",
            "South Korea"
          ],
          "primaryCompletion": "2026-03"
        }
      ],
      "sponsor_landscape": {
        "academic_sponsors": "ECOG-ACRIN, Alliance, NCI leading academic cooperative groups",
        "emerging_biotechs": [
          "Turning Point Therapeutics",
          "Blueprint Medicines",
          "Mirati Therapeutics"
        ],
        "top_industry_sponsors": [
          "Roche/Genentech (18 trials)",
          "Bristol-Myers Squibb (14)",
          "AstraZeneca (13)",
          "Merck (12)",
          "Pfizer (11)"
        ]
      },
      "mechanism_breakdown": {
        "adc": 18,
        "other": 81,
        "bispecific": 12,
        "targeted_therapy": 41,
        "chemo_combinations": 31,
        "io_checkpoint_inhibitors": 62
      },
      "pipeline_assessment": "Extremely crowded pipeline — PD-1/L1 space saturated. ADCs and bispecifics represent highest differentiation potential. KRAS G12C targeted therapies emerging as new standard.",
      "approved_drugs_context": "NSCLC has 30+ FDA-approved agents. Pipeline is additive rather than disruptive in most cases.",
      "geographic_distribution": {
        "asia_pct": 22,
        "other_pct": 5,
        "europe_pct": 28,
        "us_trials_pct": 45,
        "most_active_countries": [
          "United States",
          "China",
          "Germany",
          "South Korea",
          "Japan"
        ]
      }
    }
  }
}